Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Investing Intel. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

In the vehicles’ strongest showing since early 2022, there were eight new SPACs from April 28 through May 5. Of those eight, ...

While Merck's earnings were... SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Moderna MRNA2.15%increase; green up pointing triangle logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports.